Incyte Corp (NAS:INCY)
$ 57.05 -0.55 (-0.95%) Market Cap: 12.83 Bil Enterprise Value: 9.01 Bil PE Ratio: 17.29 PB Ratio: 2.37 GF Score: 86/100

Incyte Corp at Bank of America Merrill Lynch Global Healthcare Conference Transcript

Sep 18, 2019 / 11:10AM GMT
Release Date Price: $78.54 (-0.71%)
Unidentified Analyst

Hey, everybody. Thanks. It's my pleasure to be able to introduce our next company. I'm putting my U.S. biotech hat back on again as I did this morning while we're between biotech analysts. So our next company is Incyte. I'm very pleased to be able to introduce Hervé Hoppenot, who's the Chairman and President and CEO. I also remember Hervé from the time he's at Novartis as well, so it's like welcoming back old friends.

So Hervé has a presentation, and then we'll be able to move over to some interesting Q&A afterwards. So Hervé, I should like to give the floor to you.

HervÃ;Hoppenot
Incyte Corporation - Chairman, President & CEO

© -

Okay. Well, thank you. Thank you for inviting us. So what I was thinking could be useful in a few minutes is basically to describe a little bit all the components of Incyte here because it's a very complete picture of many different projects going on different time lines. So let's see if we can go through the forward-looking statements and a brief description of the franchise, really,

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot